nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.04.2012 | Commentary

Going past the data for temozolomide

verfasst von: J. Lee Villano, Nathalie Letarte, Linda R. Bressler

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRef

Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197PubMedCrossRef

Lai A, Filka E, McGibbon B et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380PubMedCrossRef

Vredenburgh JJ, Desjardins A, Reardon DA et al (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119–4124PubMedCrossRef

Hau P, Koch D, Hundsberger T et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68:688–690PubMedCrossRef

Khasraw M, Bell D, Wheeler H (2009) Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci 16:854–855PubMedCrossRef

Poelen J, Prick MJ, Jeuken JW et al (2009) Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma. Acta Neurol Belg 109:238–242PubMed

Stern JI, Apisarnthanarax S, Paleologos NA et al (2003) Temozolomide as long-term maintenance treatment for gliomas. Ann Neurol 54:S31–S32CrossRef

Gilbert M, Wang M, Aldape K et al (2011) RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 29:suppl; abstract 2006

10.

National Cancer Institute (2011) Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma, In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00626990

11.

National Cancer Institute (2011) Radiation therapy with or without temozolomide in treating patients with low-grade glioma, In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00978458

12.

National Cancer Institute (2011) Radiation therapy with or without temozolomide in treating patients with anaplastic glioma, In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00626990

13.

National Cancer Institute (2011) Radiation therapy or radiation therapy and temozolomide or temozolomide alone in treating patients with newly diagnosed anaplastic glioma, In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00887146

14.

Villano JL, Letarte N, Yu JM et al (2011) Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol [Epub ahead of print]

15.

FDA 2007 Temozolomide (marketed as Temodar): Aplastic anemia. Drug safety newsletter 1:7

16.

Chamberlain MC, Raizer J (2009) Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol 93:229–232PubMedCrossRef

17.

De Vita S, De Matteis S, Laurenti L et al (2005) Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol 84:760–762PubMedCrossRef

18.

Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010PubMedCrossRef

19.

Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755–5760PubMedCrossRef

20.

The Myeloma Beacon Staff (2011) Revlimid cancer controversy flares, URL: http://www.myelomabeacon.com/news/2011/02/05/revlimid-lenalidomide-cancer-controversy-flares/

21.

Tancini G, Bonadonna G, Valagussa P et al (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2–10PubMed

22.

Einhorn LH, Williams SD, Troner M et al (1981) The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 305:727–731PubMedCrossRef

23.

O’Connell MJ, Laurie JA, Kahn M et al (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295–300PubMed

Titel: Going past the data for temozolomide
verfasst von: J. Lee Villano
Nathalie Letarte
Linda R. Bressler
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1796-4

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Going past the data for temozolomide

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia

Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer

A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie